Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2017-05-12 Earnings Release
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 12, 2017, by Leap Therapeutics, Inc. It announces the company's financial results for the first quarter ended March 31, 2017, and includes a press release as an exhibit. The document explicitly states that the information is a press release and is not filed for purposes of Section 18 of the Exchange Act, indicating it is an announcement rather than a full financial report. The content is typical of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights. The document length is about 5124 characters, which is consistent with a press release rather than a full quarterly report. Therefore, the appropriate classification is Earnings Release (ER).
2017-05-12 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2017, by Leap Therapeutics, Inc. It announces the issuance of a press release containing financial results for the year ended December 31, 2016, and clinical data. The document itself is a current report notifying the market of these results, not the full financial report. The text explicitly states that the press release is attached as an exhibit and that the information is not "filed" for certain regulatory purposes. The document length is 3718 characters, which is relatively short and consistent with an announcement rather than a full report. The content matches the description of an Earnings Release (ER) as it is an initial announcement of quarterly/periodical financial results with key highlights only, rather than a full Annual Report or Interim Report. Therefore, the correct classification is Earnings Release (ER).
2017-03-31 English
10-K
Annual Report FY 2016
2017-03-31 English
3
Director's Dealing
2017-02-24 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as equity incentive plans. It includes detailed information about the securities to be registered, the plans under which they are offered, and legal and indemnification provisions. This type of filing is related to share issuance and capital changes, specifically for employee stock plans. It is not an annual report, earnings release, or any other financial report type. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and content confirm it is the actual registration statement, not just an announcement or certification.
2017-01-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.